Overland ADCT BioPharma Announced NMPA Accepts Biologics License Application and Grants Priority Review for ZYNLONTA For Treatment Of Relapsed Or Refractory Diffuse Large B-cell Lymphoma
Portfolio Pulse from Charles Gross
Overland ADCT BioPharma, a joint venture of Overland Pharmaceuticals and ADC Therapeutics SA (NYSE:ADCT), announced that the China National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for ZYNLONTA, a treatment for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in China. The BLA has been granted priority review by the NMPA.
July 24, 2023 | 11:26 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The acceptance and priority review of the BLA for ZYNLONTA by the NMPA could potentially boost ADC Therapeutics' market presence in China.
The acceptance of the BLA for ZYNLONTA by the NMPA is a significant regulatory milestone for ADC Therapeutics. The priority review status could potentially expedite the approval process, allowing the company to market the drug in China sooner. This could increase ADC Therapeutics' market presence and potentially its revenues in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100